Nilotinib Capsule
Product Images NDC 72205-238

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Nilotinib (NDC 72205-238). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Nilotinib-cap-150mg-28's-blister-label (Nilotinib Cap 150mg 28s Blister Label)

Packaging label for Nilotinib Capsules 150 mg oral capsules by Novadoz Pharmaceuticals LLC. The label includes two blister packs with capsule outlines, dosage strength prominently displayed as 150 mg per capsule, and a note to see the patient medication guide for full information. The label also includes the Novadoz logo and a statement about taking the capsules on an empty stomach.*

FDA Label Image

Nilotinib-cap-150mg-28s-inner-crtn-label (Nilotinib Cap 150mg 28s Inner Crtn Label)

Packaging label for Nilotinib Capsules 150 mg oral capsules containing 28 capsules per container. The label includes usage instructions to take capsules on an empty stomach and avoid food around dosing times. Manufactured by MSN Laboratories Private Limited, distributed by Novadoz Pharmaceuticals LLC. The label features detailed kit opening and closing directions and includes storage conditions and contact information.*

FDA Label Image

Nilotinib-cap-150mg-28s-outer-crtn-label (Nilotinib Cap 150mg 28s Outer Crtn Label)

Nilotinib Capsules 150 mg oral capsules packaging label from Novadoz Pharmaceuticals LLC. The label indicates the medication is prescription only and instructs to take capsules on an empty stomach, avoiding food for at least 2 hours before and 1 hour after dosing. The package contains 4 blister packs with 28 capsules each. Storage instructions and manufacturer info (MSN Laboratories Private Limited, India) are also present.*

FDA Label Image

Nilotinib-cap-200mg-28's-blister-label (Nilotinib Cap 200mg 28s Blister Label)

Packaging label for Nilotinib Capsules 200 mg by Novadoz Pharmaceuticals LLC. The label shows a blister pack illustration with capsules arranged in rows, a dosage strength of 200 mg per capsule clearly indicated, and the brand name Novadoz with its slogan. The label advises taking nilotinib capsules on an empty stomach and refers to the patient medication guide for additional information.*

FDA Label Image

Nilotinib-cap-200mg-28s-inner-crtn-label (Nilotinib Cap 200mg 28s Inner Crtn Label)

Packaging label for Nilotinib Capsules 200 mg oral capsules by Novadoz Pharmaceuticals LLC. The label includes instructions for opening and closing the kit and patient guidance to take capsules on an empty stomach, avoiding food two hours before and one hour after dosing. The package contains 28 capsules and includes storage instructions and a barcode.*

FDA Label Image

Nilotinib-cap-200mg-28s-outer-crtn-label (Nilotinib Cap 200mg 28s Outer Crtn Label)

Packaging label for Nilotinib Capsules 200 mg oral capsules by Novadoz Pharmaceuticals LLC. The label instructs dispensing the medication guide to patients and taking capsules on an empty stomach, avoiding food at least 2 hours before and 1 hour after dosing. The package contains 4 individual blister packs with 28 capsules each. Manufacturer is MSN Laboratories Private Limited, India.*

FDA Label Image

Nilotinib-cap-50mg-120s-cntr-label (Nilotinib Cap 50mg 120s Cntr Label)

Nilotinib Capsules 50 mg oral capsules label from Novadoz Pharmaceuticals LLC. The label indicates 120 capsules per bottle with storage instructions, manufacturer MSN Laboratories Private Limited, and distributor Novadoz Pharmaceuticals LLC. It includes medication guide information and dosage precautions to take capsules on an empty stomach.*

FDA Label Image

Nilotinib-cap-fig-1 (Nilotinib Cap Fig 1)

A Kaplan-Meier curve depicting treatment-free survival (%) over time in weeks since treatment-free remission (TFR) initiation. The graph shows a decreasing survival rate with censored observations marked. Additional data include patients at risk and events occurring at various time points up to 132 weeks.*

FDA Label Image

Nilotinib-cap-fig-2 (Nilotinib Cap Fig 2)

A Kaplan-Meier survival curve chart showing treatment-free survival percentage over time in weeks. The solid line represents survival estimates, with dashed lines indicating confidence intervals. Patient numbers at risk and event counts are listed below the time axis, detailing observation and censoring data.*

FDA Label Image

Nilotinib-cap-structure (Nilotinib Cap Structure)

Chemical structure of nilotinib showing its molecular composition including multiple aromatic rings and functional groups such as trifluoromethyl, amides, and heterocyclic rings, with associated hydrochloride and hydrate components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.